INVITED OBITUARY

In Memoriam Geoffrey Burnstock: Creator of Purinergic Signaling

Alexei Verkhratsky1,2,*, Herbert Zimmermann3, Maria P. Abbracchio4, Peter Illes5, Francesco DiVirgilio6

1Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PT, UK, 2Achucarro Centre for Neuroscience, IKERBASQUE, 48011 Bilbao, Spain, 3Institute of Cell Biology and Neurobiology, Molecular and Cellular Neurobiology, Goethe-University, Frankfurt am Main, Germany, 4Department of Pharmacological Sciences, Laboratory of Molecular and Cellular Pharmacology of Purinergic Transmission, University of Milan, Milan, Italy, 5Rudolf Boehm Institute for Pharmacology and Toxicology, University of Leipzig, Germany, 6Department of Medical Sciences, University of Ferrara, Ferrara, Leipzig, Italy

*Corresponding author. E-mail: alexej.verkhratsky@manchester.ac.uk

Abstract

Geoff Burnstock (1929–2020) discovered purinergic signaling in a fastidious research that started in early 1960 and culminated in a concept of purinergic nerves in 1972. Subsequently, Geoff developed the concept of purinergic transmission and demonstrated ATP storage, release, and degradation in the context of cotransmission, which was another fundamental concept developed by him. Purinergic transmission contributes to the most fundamental physiological functions such as sensory transduction, regulation of heart rate, smooth muscle contraction, bile secretion, endocrine regulation, immune responses, as well as to various pathophysiological conditions, including inflammation, cancer, neuropathic pain, diabetes, and kidney failure.

Key words: ATP; purinergic signaling purinoceptors; vesicular release; ectonucleotidases; inflammation

I would like to remind the reader of the extraordinary influence of fashionable concepts in science. Gifted and meticulous workers will perform remarkable contortions to fit their data into accepted dogma, especially if established by powerful and brilliant personalities at the forefront of the field. They will often dismiss or ignore data that fall outside interpretation by current theory, searching hard for technical or artefactual explanations. Once a new attitude becomes acceptable, then the same data can be miraculously redeployed to support it.

Geoffrey Burnstock’s (Figure 1) journey of life came to a sad end on June 3, 2020 but what a journey it was! Geoff was born in 1929, which was also the year of birth of ATP, the molecule of life that was at the very core of Geoff’s academic career. ATP was discovered almost simultaneously in the United States and Germany; Cyrus Hartwell Fiske and Yellagaprada SubbaRow were the first to describe ATP in Harvard, probably as early as in 1926. Nonetheless, Karl Lohmann who did similar experiments in Berlin (under the imaginative supervision of Otto Meyerhoff) was first to publish. Lohmann paper appeared in Naturwissenschaften in August, whereas Fiske and SubbaRow managed to have their story printed in Science in October 1929. Very soon Fritz Lipman introduced the concept of the “high-energy phosphate bond” and ATP became firmly associated with cell energetics. The year 1929 also witnessed the seminal

Submitted: 20 June 2020; Accepted: 22 June 2020

© The Author(s) 2020. Published by Oxford University Press on behalf of American Physiological Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
discovery of Alan Drury and Albert Szent-Györgyi von Nagyrapolt who found that a nucleoside adenosine and adenylic acid (adenosine-5’-monophosphate, 5’-AMP) act as signaling molecules in the cardiovascular system.5 Thus, the set for Geoff’s scientific life was set.

ATP as a Neurotransmitter: Fighting Against the Odds

“Of known natural processes that might pass on excitation, only two are, in my opinion, worth talking about. Either there exists at the boundary of the contractile substance a stimulative secretion in the form of a thin layer of ammonia, lactic acid, or some other powerful stimulatory substance, or the phenomenon is electrical in nature”.6 This sentence written by Emil Du Bois-Reymond in 1877 opened the era of intercellular signaling mediated by molecules moving between cells through gap junctions or by chemical transmitters secreted by the cells and acting on specific sites located on the plasma membrane. The synapse (syn, σύν in meaning together and haptēn σχέδιον meaning clasp) as a structure connecting nerve cells was defined by Michael Foster and Charles Scott Sherrington in 1897.7 The principles of chemical neurotransmission were laid down by John Newport Langley and Thomas Renton Elliott in the early years of the 20th century. Elliott suggested that epinephrine can be a neurotransmitter, while Langley defined neurotransmitter receptors as “receptive substances... capable of receiving and transmitting stimuli of target cells”.8–10 The first neurotransmitter acting through diffusion and binding to specific receptors was acetylcholine discovered by Otto Loewi.11 Noradrenaline was experimentally proven to act as a neurotransmitter in 1946;12 γ-aminobutyric acid (GABA) and glycine were identified and accepted as bona fide inhibitory neurotransmitters in the 1970s,13–15 while it took about 20 years for glutamate to be included into the class of neurotransmitters.16,17

The emergence of ATP and purinergic neurotransmission began in the 1960s when Geoff Burnstock (who was in those days a Senior Lecturer and then Professor of Zoology at the University of Melbourne) discovered and characterized a nonadrenergic, noncholinergic (NANC) neurotransmission in the peripheral nervous system (Figure 2).19–21 First, in 1966, Geoff (together with Anne Smythe) performed experiments inspired by Otto Loewy’s seminal study; but the results were only published many years later, in 2010.22 Geoff and Anne demonstrated that stimulation of NANC nerves to the taenia coli fixed in a top chamber produced the typical nerve-mediated response (fast relaxation, followed by rebound contraction), while the perfusate from this muscle produced a slower relaxation (without rebound contraction) when being fed into a taenia coli preparation in the lower chamber (Figure 3). Years
The theory of purinergic transmission was finally conceptualized in 1972 in one of the most famous (over 1600 citations) papers published in Pharmacological Reviews.\(^2\) This theory was not immediately accepted, the academic community was enchanted by ATP’s role as an energy source; and this spell precluded the realization that so precious a molecule can be wasted by secretion. Of course, at that time, the concept that cells could use a “primitive” molecule involved in metabolism and energy production for highly specific and “noble” functions such as cell-to-cell communication was far beyond anyone’s understanding. Nor was it suspected that the amount of ATP utilized for secretion and extracellular signaling only accounted for an infinitesimal part of the total cellular ATP pool.

The concept of ATP also being used a transmitter even inspired poems, like the one written by Prof. Samuel C. Silverstein in honour of Geoff Burnstock:

*Oh tell me Lord how could be,  
That though our cells make ATP  
It’s not all used for energy,  
But sometimes is secreted free.  
It puzzles you, it puzzles me  
While Geoffrey Burnstock smiles with glee  
At the many roles of ATP.*

Geoff’s intuition, *in tempore non suspecto*, of the dual role of ATP was absolutely unconventional and “out of the box”. Geoff used to say that if you want to do good science, you have to be “anarchic,” and that to advance knowledge you need to break dogmas. When Geoff was a PhD student at University College London (UCL) together with his best life-long friend and loyal opponent Eric Barnard, they were both part of a Society called “The Challengers” formed by young UCL students who used to meet one night per week to discuss how to break a science dogma.

It took almost quarter of a century for purinergic neurotransmission to become universally accepted. Geoff led this fight and inspired cohorts of followers all over the world, thus finally breaking the resistance and justifying purines as widespread neurotransmitters.
Figure 4. Evidence for ATP as a NANC Neurotransmitter. (A) Left-hand side: responses of the guinea pig taenia coli to NANC nerve stimulation (NS, 1 Hz, 0.5 ms pulse duration, for 10 s at supramaximal voltage) mimicked by ATP (2 × 10⁻⁶ M). The responses consist of a relaxation followed by a “rebound contraction.” Atropine (1.5 × 10⁻⁷ M), guanethidine (5 × 10⁻⁷ M), and sodium nitrite (7.2 × 10⁻⁴ M) were present. Right-hand side: a comparison of the NANC contractile responses of the guinea pig bladder strip to intramural nerve stimulation (NS: 5 Hz, 0.2 ms pulse duration and supramaximal voltage) mimicked by exogenous ATP (8.5 × 10⁻⁶ M). Atropine (1.4 μM) and guanethidine (3.4 μM) were present throughout. (B) Effect of changing the calcium ion (Ca²⁺) concentration on the release of ATP (measured with the firefly luciferin/luciferase technique) from the guinea pig isolated bladder strip during stimulation of NANC nerves. Upper trace: mechanical recording of changes in tension (g) during intramural nerve stimulation (NS: 20 Hz, 0.2 ms pulse duration, supramaximal voltage for 20 s). Lower trace: concentration of ATP in consecutive 20 s fractions of the superfusate. The Ca²⁺ concentration in the superfusate varied as follows: (1) 2.5 mM (normal Krebs); (2) 0.5 mM; (3) 0.25 mM; (4) 2.5 mM. The successive contractions were separated by 60 min intervals as indicated by the breaks in the mechanical trace. Atropine (1.4 μM) and guanethidine (3.4 μM) were present throughout. (C) The purinergic neuromuscular transmission hypothesis depicting the synthesis, storage, release, and inactivation of ATP. ATP, stored in vesicles in nerve varicosities, is released by exocytosis to act on postjunctional P2 purinceptors on smooth muscle. ATP is broken down extracellularly by ATPases and 5'-nucleotidase to adenosine, which is taken up by varicosities to be resynthesized and restored in vesicles. If adenosine is broken down further by adenosine deaminase to inosine, it is removed by the circulation. Figure is reproduced with permission from Burnstock and Verkhratsky.

The Concept of Cotransmission

Another fundamental contribution of Geoff Burnstock to the general theory of neurotransmission lies in defining cotransmission in both the peripheral and central nervous systems. ATP and noradrenaline (NA) released from small granular vesicles (SGVs) act on F2X and α₁ receptors on smooth muscle, respectively. ATP acting on ionotropic F2X receptors evokes excitatory junction potentials (EJPs), increase in intracellular calcium ([Ca²⁺]i), and fast contraction; while occupation of metabotropic α₁-adrenoceptors leads to production of inositol trisphosphate (IP3), increase in [Ca²⁺]i, and slow contraction. Neuropeptide Y (NPY) stored in large granular vesicles (LGVs) acts after release both as a prejunctional inhibitory modulator of release of ATP and NA and as a postjunctional modulatory potentiator of the actions of ATP and NA. Soluble nucleotidases are released from nerve varicosities and are also present as ectonucleotidases. Redrawn from Burnstock and reproduced from Burnstock and Verkhratsky.

Figure 5. Schematic of Sympathetic Cotransmission as Drawn by Geoff Burnstock. ATP and noradrenaline (NA) released from small granular vesicles (SGVs) act on F2X and α₁ receptors on smooth muscle, respectively. ATP acting on ionotropic F2X receptors evokes excitatory junction potentials (EJPs), increase in intracellular calcium ([Ca²⁺]i), fast contraction; while occupation of metabotropic α₁-adrenoceptors leads to production of inositol trisphosphate (IP3), increase in [Ca²⁺]i, and slow contraction. Neuropeptide Y (NPY) stored in large granular vesicles (LGVs) acts after release both as a prejunctional inhibitory modulator of release of ATP and NA and as a postjunctional modulatory potentiator of the actions of ATP and NA. Soluble nucleotidases are released from nerve varicosities and are also present as ectonucleotidases. Redrawn from Burnstock and reproduced from Burnstock and Verkhratsky.

Purinoceptors: The P1/P2 and P2X/P2Y Divide

The difference in the biological actions of ATP and adenosine was noted quite early; Gillespie reported, already in 1934, that ATP is most potent in relaxing guinea pig ileum, whereas adenosine is more potent in promoting vasodilatation of coronary arteries. Many more examples of pharmacological differences between ATP and adenosine have been since accumulated. Analysis of these differences prompted Geoff to invent the first grand classification of purinoceptors; he suggested to divide them all into two major classes of P1 (adenosine and AMP) and P2 (ATP and ADP) receptors. This classification became widely used and popular. Adenosine receptors have been further subclassified into A₁, A₂A, A₂B, and A₃ receptors. The P2 ATP receptors were also in need of stratification, as ATP on its own...
clearly demonstrated both ionotropic and metabotropic capabilities and in 1985 Geoff (together with Charles Kennedy) classified \( P_2 \) receptors into \( P_2X \) and \( P_2Y \). This classification was further refined in 1999 when \( P_2X \) receptors were defined as belonging to ionotropic, whereas \( P_2Y \) to metabotropic families. Recently, the adenine receptors were proposed to constitute a separate family of \( P_2O \) receptors in rodents. In the 1990s, molecular cloning identified seven \( P_2X \) (\( P_2X_{-7} \)) receptors and eight (\( P_2Y_{1,2,4,6,11,12,13,14} \) mammalian \( P_2Y \) receptors.

Geoff together with his friend and colleague Eric Barnard cloned and characterized the first representative of the \( P_2Y \) receptor family, the \( P_2Y_1 \) receptor from an embryonic chick whole brain cDNA library. Subsequently, in cooperation with John Wood, Geoff participated in cloning and characterization of \( P_2X_3 \) receptor. This receptor was unique in that ATP application induced through it a rapidly desensitizing ionic current and that its expression was mostly segregated to a subset of sensory neurons of the dorsal root ganglia. After these initial studies, the role of \( P_2X_3 \) receptors has been widely demonstrated in the physiological regulation of the central and peripheral nervous systems, the cardiovascular, respiratory, and immune systems, as well as in various pathological conditions. As a result, \( P_2X \) and \( P_2Y \) receptors have gained widespread clinical interest with agonists and antagonists currently undergoing clinical trials; these medicines have therapeutic potential for a broad spectrum of diseases, including thrombosis and stroke, dry eye, atherosclerosis, kidney failure, osteoporosis, bladder incontinence, colitis, neurodegenerative diseases, pain, and cancer (for a more detailed description, the reader is referred to a recent review by Burnstock). Based on the discovery of \( P_2X_4 \) receptors, more recently gefapixant, an orally bioavailable and peripherally restricted \( P_2X_3 \) receptor antagonist has been synthesized and explored for its therapeutic potentials in humans. The first two letters (Ge) are an abbreviation of Geoffrey’s name to honor his merits. In late phase clinical trials, this drug was found to be suitable to suppress chronic cough, but unfortunately, it also caused a high prevalence of alterations in taste sensitivity.

**ATP Storage, Release, and Degradation**

The criteria for ATP acting as a neurotransmitter highlighted in the seminal paper published by Burnstock et al. in 1970 include the demonstration of cellular storage and release. Organellar storage of ATP had previously been demonstrated for chromaffin granules, for noradrenaline-storing granules isolated from splenic nerves, and granules from blood platelets. Storage of ATP in electron-lucent synaptic vesicles was demonstrated somewhat later. Since large granular vesicles were previously found in axonal profiles in the gut, it was obvious to assume that these also function as storage sites for ATP in NANC inhibitory nerves. Major research lines followed to further elucidate the functional role of ATP in vesicles and granules. The acridine derivative quinacrine (earlier on used for treatment of malaria), which binds ATP could be used to depict cellular storage of ATP using a fluorescence histochemical method. In their important study on the guinea pig urinary bladder, Burnstock et al. identified quinacrine-positive cells that were different from those observed with catecholamine fluorescence and cholinesterase histochemistry, providing further support for the concept that the NANC excitatory nerves supplying the guinea pig bladder are purinergic. This was then followed by many studies using quinacrine—also from Geoff Burnstock’s lab—to identify purinergic nerves. Among others, this allowed the demonstration of the coexistence of ATP and nitric oxide (another inhibitory component) in NANC inhibitory neurons.

The molecular analysis of isolated granules and vesicles added a new twist to purinergic signaling. Not only ATP and biogenic amines but also other nucleotides such as ADP, GTP, UTP, and even the dinucleoside polyphosphates Ap2A and Ap4A—but not nucleosides—were identified in both chromaffin granules and cholinergetic vesicles. These nucleotides were stored in the millimolar range. Concentrations were always highest for ATP reaching estimated values around 500 mM. In accordance with these findings, it could later be shown that—depending on subtype—nucleotide receptors can also respond to ADP, dinucleoside polyphosphates, UTP, UDP, and UDP-glucose. It thus became clear that the mechanisms of vesicular nucleotide storage and release were of essential relevance for purinergic signaling. These were characterized in detail in the nervous system, where ATP is stored in dedicated vesicles as well as costored with other transmitters such as glutamate and GABA. Studies initially concentrated on the molecular and functional characterization of vesicular and granular membrane components as well as the kinetics of nucleotide uptake. While it could be shown that nucleotide uptake into noradrenaline-containing storage granules is energized by an ATP-driven electrochemical gradient with a mean substrate concentration for half saturation of the transport system of about 1–2 mM, the molecular identity of the transporter remained elusive. In 2008, the vesicular nucleotide transporter (VNUMT) was finally cloned and characterized. This turned out to be a milestone in purinergic signaling in several ways. The SLC17A9 gene encoding VNUMT is present in all animals, further underlining the ubiquity of purinergic mechanisms in the animal kingdom. Similarly, VNUMT is widely distributed throughout the body and cellular systems in accordance with the wide distribution of nucleotide receptors and nucleotide signaling pathways in essentially all principal cell types. Moreover, VNUMT colocalizes with the vesicular glutamate, GABA, and acetylcholine transporters VGLT1, VGAT, and VAChT, respectively, and is expressed in tyrosine hydroxylase-positive dopaminergic neurons of the substantia nigra and ventral tegmental area, and in subpopulations of rat dorsal root ganglion neurons. All this beautifully underlines the earlier notion of Geoff Burnstock that ATP acts as a cotransmitter with classical neurotransmitters. Finally, in VNUMT gene knockout mice vesicular ATP release was shown to be blocked in various cellular systems, including neurons and chromaffin cells underlining the important role of exocytosis for cellular ATP release.

In their seminal 1970 paper, Burnstock et al. demonstrated release of ATP from nonadrenergic inhibitory nerves of the gut. It had previously been shown that ATP can be released from antidromically stimulated sensory nerves and also from the adrenergic medulla. Yet, while vesicular or granular release was a likely source, it soon turned out that ATP can also be released from non-neuronal cells and by additional mechanisms not involving stored ATP. This further nourished the skepticism of many scientists that ATP release is an artifact and represents leakage from broken or dying cells. The large and negatively charged ATP molecules cannot diffuse through a lipid bilayer. Research of the past two decades has established that cellular release of ATP is far more complicated and that—depending on cell type—several mechanisms are employed. The particular mechanism of ATP release is associated with membrane channels with anion permeability and a large ion-conducting pore. Several molecular complexes have been discussed and are now
acknowledged to mediate the physiological release of cytosolic ATP. These include connexin hemichannels, pannexin 1, calcium homeostasis modulator 1 (CALHM1), volume-regulated anion channels (VRACs, also known as volume-sensitive outwardly rectifying anion channels), and maxi-anion channels. Another promising candidate for an ATP release channel is the P2X\_ receptor complex. Thus, the issue is far more complicated than initially anticipated and adds a further puzzle to be solved in the purinergic signaling field.

Extracellular hydrolysis of ATP had been shown early on with spermatozoa or blood cells and in many preparations, the breakdown of released ATP to adenosine could be observed. Breakdown of ATP had also been observed by Burnstock et al. in chicken stomach preparations. Accordingly, Geoff Burnstock had laid out the entire extracellular hydrolysis chain from released ATP via ADP and AMP to adenosine followed by reuptake of the nucleoside for resynthesis of ATP and vesicular reloading (see Figure 5). While this was extremely imaginative, the molecular players involved in extracellular nucleotide hydrolysis were still enigmatic. The first ectonucleotidase cloned and characterized in molecular terms was the enzyme nonspecific of alkaline phosphatase followed by ecto-5'-nucleotidase and finally an ecto-apyrase, which was later renamed ecto-nucleoside triphosphate diphosphohydrolase 1 (NTPDase-1). Surprisingly, it turned out that there was an entire protein family of NTPDases (eight paralogues) with differing hydrolysis profiles and even more groups of enzymes for hydrolysis of ATP (ecto-nucleotide pyrophosphate/phosphodiesterases, NPP1 to NPP4), several alkaline phosphatases were identified and there were AMP hydrolyzing enzymes other than ecto-5'-nucleotidase (alkaline phosphatase, prostatic acid phosphatase). There is also interconversion leading to the extracellular formation of ATP from its breakdown products. Finally, some of these enzymes also occur in soluble form. The differential cellular distribution of these enzymes and their catalytic properties provides a further challenge to understanding the physiology and pathophysiology of purinergic signaling.

Ancient and Ubiquitous Purinergic Transmission

Geoff was very much interested in the evolution of purinergic transmission. He clearly recognized and described a long evolutionary history of purinergic transmission, and the tight links with the fundamentals of the genetic code and bioenergetics. Geoff proposed that ATP could have been the “first” molecule during evolution to communicate messages to other cells. His idea was based, first, on the fact that any kind of cell does synthesize and utilize ATP, and, second, that P2X receptors share topological membrane organization with epithelial voltage-gated sodium channels. Geoff used to say that when, during evolution, cells experienced the need to send a message to other cells, they “decided” to secrete something that was present in huge amounts inside the cells themselves—that is ATP. To communicate its message to nearby cells, secreted ATP “induced” some already existing entity that was present on the extracellular membrane of nearby cells to recognize itself as a message. Primitive voltage-gated epithelial sodium channels were thus induced to specialize themselves to recognize ATP. Geoff used to conclude that this could have been how voltage-gated channels had turned into ligand-operated receptors. These views were presented by Geoff at a Ciba Foundation meeting in London in 2005, thus instigating an exciting, smart, and exhilarating discussion between Geoff and Eric Barnard, whose comment to Geoff’s theory was “If I were a neurone, I would not use ATP as a transmitter.”

Geoff also very clearly perceived the omnipresence of purinergic transmission widespread between species. Bacteria, although not possessing a classical purinoceptor are sensitive to ATP which acts as a danger signal; the Dictyostelium discoidum is the earliest species to express ionotrophic P2X-like Dd2PX receptor and metabotropic receptors to cAMP, known as cAR1-4 receptors, which are ancestors of P2Y receptors. Purinergic transmission is present in algae, in plants, in fungi and throughout the animal kingdom. Furthermore, purinergic transmission is unique in its pluripotency and omnipresence. Most neurotransmitters are segregated around the body: for example, glutamate and GABA are operative in the brain, glycine is the main inhibitory transmitter in the spinal cord. Acetycholine has a wider spread being deployed not only in the peripheral nervous system and in a subpopulation of cholinergic neurons in the brain, but acting as a transmitter in other organs. Adrenaline and noradrenaline have a somewhat wider reach acting as central neurotransmitters and circulating hormones. The purinergic system, has no boundaries acting in all organs, tissues, and systems, mediating rapid as well as long-lasting effects because almost every cell does have at least one type of purinoceptors. Most fundamental physiological functions such as sensory transduction, regulation of heart rate, smooth muscle contraction, bile secretion, endocrine regulation, immune responses, as well as various pathophysiological conditions, including neuropathic pain, diabetes, kidney failure, and cancer, are regulated by purinergic signaling. Finally, activation of P2X receptors signals the very beginning of life: using this pathway ATP induces the acrosome reaction which is needed for sperm to fuse with the oocyte plasma membrane and subsequent successful fertilization.

Purinergic Signaling in the Central Nervous System

After discovering the role of ATP as an extracellular signaling molecule in the peripheral nervous system, it was only natural that Geoff should turn his attention to the brain. Frances Edwards et al. were the first to describe the role of ATP as a rapid neurotransmitter in the medial habenula; subsequently numerous studies characterized ATP as a fast neurotransmitter in several brain regions in various areas of the brain contributing to fast neuro-neuronal synaptic communication. The noradrenergic cells of the nucleus locus coeruleus were found to exhibit P2X receptor-mediated excitatory postsynaptic currents (EPSCs) and \( \alpha_{1} \)-adrenoceptor-mediated inhibitory postsynaptic currents (IPSCs), indicating cotransmission mediated by ATP and noradrenaline. However, when the brain and spinal cord were electrophysiologically mapped in search for ATP-mediated fast neurotransmission, it turned out that relatively few areas utilize fast ATP signaling via P2X receptors. Furthermore, ATP-mediated ECSCs caused by stimulation of postsynaptic P2X receptors were relatively small, infrequent, only observed in a subpopulation of neurons, and strong electrical stimulation was required to evoke those.

It was an important discovery that ATP is released by exocytosis from neurons and neuroglia, although the transporter-mediated and diffusion/channel-mediated release of ATP from glial cells is probably of equal significance. The different temporal resolution of purinergic signaling is of utmost significance;
while P2X receptors mediate fast responses in the millisecond-range, P2Y receptors mediate responses in the range of seconds, hours, or even days/weeks by interacting with cytoplasmic signaling cascades and growth factors. In addition, ATP released by neurons may activate glial P2X/Y receptors and vice versa, ATP secreted from neuroglial cells may functionally feedback to neuronal purinoceptors (Figure 6). Purinergic signaling, therefore, appears as the main pathway for neuronal–glial reciprocal communications, while ATP secreted by both neurons and neuroglia contributes to the regulation of various aspects of neuroplasticity.

Geoff never forgot that basic science provides the background on which applied science is building up. He consequently looked for the applicability of his findings for the benefit of patients. While studying the role of ATP in neuron–neuron and neuron–glial communications, he always wanted to decipher the behavioral consequences of this interaction. For example, in 2011, he found that astrocytic ATP is able to modulate memory in chicks. This was an important extension of the previous findings that purinergic pathways are related to feeding behavior, locomotor coordination, sleep, and arousal, as well as mood and motivation.

Geoff’s primary interest in the last decades of his life was in neurodegeneration and regeneration of nervous tissue. He wrote many conceptual review articles on the involvement of ATP in brain injury, stroke, ischemia, epilepsy, chronic pain, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis. He found it fascinating that ATP and its receptors appear to be major players in the etiology of psychiatric disorders such as major depression, bipolar disorder, autism, and addiction. With respect to neuroregeneration, he identified P2 receptors whose blockade inhibited the

**Figure 6.** Omnipresence of Purinergic Signaling Pathways in Neuronal–Glia Circuits. The microarchitecture of the gray matter (as shown in the center) is defined by astroglial domains, composed of astrocyte, neighboring blood vessel encompassed by astroglial end feet and neurons residing within astroglial territory—the neuro-gio-vascular unit. The microglial cells (each also having its own territory) are constantly surveying these domains spying for damage. ATP and its derivatives act as an extracellular signaling molecule at all levels of communications within neuronal–glial networks. Within the astroglial synaptic cradle formed by perisynaptic astrocytic processes (I), ATP released during synaptic transmission, activates astrocytic receptors, which in turn initiate Ca\(^{2+}\) signals and Ca\(^{2+}\) waves in astroglial syncytia. Astroglial is capable of releasing ATP, which feeds back to neurons via activation of pre- and postsynaptic P1 and P2 receptors. ATP released from astrocytes (II) triggers and maintains astroglial Ca\(^{2+}\) waves. Finally, ATP released from all types of neural cells control activation (III) of microglia. Redrawn and modified from Verkhratsky et al.

Downloaded from https://academic.oup.com/function/article-abstract/1/1/zqaa006/5862644 by guest on 21 July 2020
injury-induced proliferation of olfactory epithelium progenitor cells of the adult mouse.94 This was in excellent agreement with the localization of a plethora of P2 receptors at embryonic and adult neural progenitor cells in the rodent and human brain.95

Geoff was not only a most original scientist, who made many seminal discoveries but he continuously developed, based on these discoveries, the most inspiring hypotheses, which continuously fertilized the field of purinergic signaling. Here it is probably worth referring to a minor touch of Geoff’s genius that influences purinergic research. In 2009, he proposed a hypothesis for the purinergic basis of acupuncture.96 This stirred the field and initiated quests for purines and purinoceptors in acupuncture studies.97,98

Purinergic Signaling Extends into Pathology

We were all taught in Medical School that tissue damage triggers inflammation with the associated canonical signs: Rubor, Tumor, Calor, Dolor (Aulus Cornelius Celsius, De Medicina) with Galen’s addition of Functio laesa. It has always been clear to every pathologist that injured tissues release factors that are able to signal damage, alert resident immune cells, start and amplify inflammation. Many investigators have been long intrigued by the molecular identity of these hypothetical “alarm factors,” even more so after we all became aware that cells might also die by a “silent” death (apoptosis) that, as opposed to necrosis, minimizes stimulation of the inflammatory system.

We now know that the most powerful and ubiquitous “alarm factor” (or damage-associated molecular pattern (DAMP)) released from any injured tissue is ATP, nothing else than adenosine 5’-triphosphate.99 With hindsight, this seems all too obvious, given the biochemical properties of ATP and the large ATP concentration gradient between the interior of the cell and the extracellular space. However, it is only after Geoff Burnstock put forward his hypothesis on the extracellular signaling role of ATP that biologists, immunologists, pathologists, and all other life science students started to realize that ATP is much more than the universal biological energy currency.

ATP: The Perfect Extracellular Danger Messenger

The concept that ATP is an extracellular messenger, and a signal of danger, was so obvious (maybe too obvious?) that paradoxically it was resisted by most investigators. Yet, ATP has all the key features of the perfect DAMP: basically nil extracellular concentration versus very high intracellular level, high mobility in the aqueous extracellular milieu, a very efficient extracellular degrading system to prevent desensitization, specific plasma membrane receptors. Another serious objection was raised to question the validity of the purinergic hypothesis outside the nervous system: there is no evidence that ATP accumulates to any extent in non-neuronal tissue. This was a considerable obstacle to the acceptance of an extracellular signaling role of ATP. There was of course in vitro evidence that many different cell types released ATP via multiple pathways (ABC transporters, connexin-43, pannexin-1, secretory vesicles), but no solid experimental proof that this might occur in vivo. The turning point was the introduction of a genetically encoded bioluminescent probe (the pmeLUC probe) that allowed semiquantitative in vivo measurement of the ATP concentration in the pericellular space.100 Thanks to the pmeLUC probe we now know that ATP accumulates into the extracellular space during bacterial infections, allogeneic reactions, autoimmune reactions, traumas, and of course at tumor sites.

ATP and Purinergic Receptors: Partners in Inflammation

Of course, any DAMP, and ATP is no exception, is by definition a potent proinflammatory stimulus. Ample experimental evidence supports the original view that a host of injurious agents and pathogens trigger ATP release from virtually all cell types. Released ATP in turn acts as an autoparacrine stimulus to activate inflammatory cells through P2Y and P2X purinoceptors. The P2Y/P2X receptor classification42,43 found a fertile application to inflammation. It was soon realized that all immune cells express P2Y and P2X receptors, a feature that confers on the immune response an enormous plasticity. P2Y and P2X receptors are involved in inflammatory pain, inflammatory edema, release of inflammatory mediators, production of reactive oxygen and nitrogen species, chemotaxis, proliferation, differentiation, immune cell metabolism, necrosis, necroptosis, and apoptosis.101 A paradigmatic example is the P2X4 receptor that is now recognized to be one of the most potent stimulants of the NLRP3 inflammasome and of interleukin-1β release, and therefore a key trigger of inflammation.

ATP and Purinergic Receptors Are Key to Inflammatory Homeostasis and in Host–Tumor Interaction

Inflammation is a tightly controlled homeostatic system. Any homeostatic system is based on feed-forward and feed-back control mechanisms working in close association. Geoff Burnstock’s discovery of the extracellular role of ATP paved the way for a thorough understanding of the role of extracellular adenosine in immunity and inflammation. The large majority of adenosine is generated in the extracellular space at the expense of ATP thanks to powerful and ubiquitous ectonucleotidases, for example, CD39 and CD73.102 One of the most important breakthroughs in recent years has been the discovery of the immunosuppressant function of adenosine.103 This discovery has far-reaching implications in immunology and more importantly in cancer. It is now an established fact that the tumor microenvironment (TME) is highly immunosuppressive due to the accumulation of agents that inhibit antitumor T and NK lymphocyte responses. One of the most potent immunosuppressants in the TME is adenosine generated by the hydrolysis of ATP that accumulates to very high levels in this restricted environment.104 On the contrary, extracellular ATP itself in the TME has multiple roles, tumor-promoting, by supporting tumor cell proliferation, or tumor-suppressing, by fuelling the anticancer immune response. Again, differential expression of P2Y and P2X receptors by tumor cells and tumor-infiltrating inflammatory cells confers an extraordinary plasticity to purinergic signaling in cancer. One of the most remarkable consequences has been the application of this knowledge to cancer therapy: over 50 clinical studies are ongoing to test the effectiveness of adenosine receptor blockade in different types of cancer. This would not have been possible without Geoff Burnstock’s intuition of the extracellular messenger role of ATP.

As Geoff Burnstock might reply to those who belittled his prophetic vision of the role of extracellular ATP: “There are more things in heaven and earth, Horatio, than are dreamt of in
your philosophy.” This is what we learned from Geoff: there is more in life and science than we ever dreamt.

**Authors’ Contribution**

All authors contributed equally to this work.

**Conflict of interest statement**

The authors have declared that no conflict of interest exists.

**References**


